These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

228 related articles for article (PubMed ID: 20680095)

  • 1. Targeted Therapies in Lung Cancer.
    Chirieac LR; Dacic S
    Surg Pathol Clin; 2010 Mar; 3(1):71-82. PubMed ID: 20680095
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Advances in treatment of lung cancer with targeted therapy.
    Cagle PT; Chirieac LR
    Arch Pathol Lab Med; 2012 May; 136(5):504-9. PubMed ID: 22540298
    [TBL] [Abstract][Full Text] [Related]  

  • 3. The place of targeted therapy in the patient management of non-small cell lung cancer.
    Thatcher N
    Lung Cancer; 2007 Aug; 57 Suppl 2():S18-23. PubMed ID: 17686441
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Erlotinib: CP 358774, NSC 718781, OSI 774, R 1415.
    Adis International Ltd
    Drugs R D; 2003; 4(4):243-8. PubMed ID: 12848590
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Role of epidermal growth factor receptor in lung cancer and targeted therapies.
    Liu TC; Jin X; Wang Y; Wang K
    Am J Cancer Res; 2017; 7(2):187-202. PubMed ID: 28337370
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Molecularly targeted therapy based on tumour molecular profiling versus conventional therapy for advanced cancer (SHIVA): a multicentre, open-label, proof-of-concept, randomised, controlled phase 2 trial.
    Le Tourneau C; Delord JP; Gonçalves A; Gavoille C; Dubot C; Isambert N; Campone M; Trédan O; Massiani MA; Mauborgne C; Armanet S; Servant N; Bièche I; Bernard V; Gentien D; Jezequel P; Attignon V; Boyault S; Vincent-Salomon A; Servois V; Sablin MP; Kamal M; Paoletti X;
    Lancet Oncol; 2015 Oct; 16(13):1324-34. PubMed ID: 26342236
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Targeted therapies for non-small cell lung cancer.
    Dempke WC; Suto T; Reck M
    Lung Cancer; 2010 Mar; 67(3):257-74. PubMed ID: 19914732
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Advanced targeted therapies in cancer: Drug nanocarriers, the future of chemotherapy.
    Pérez-Herrero E; Fernández-Medarde A
    Eur J Pharm Biopharm; 2015 Jun; 93():52-79. PubMed ID: 25813885
    [TBL] [Abstract][Full Text] [Related]  

  • 9. First-line treatment of advanced epidermal growth factor receptor (EGFR) mutation positive non-squamous non-small cell lung cancer.
    Greenhalgh J; Dwan K; Boland A; Bates V; Vecchio F; Dundar Y; Jain P; Green JA
    Cochrane Database Syst Rev; 2016 May; (5):CD010383. PubMed ID: 27223332
    [TBL] [Abstract][Full Text] [Related]  

  • 10. U.S. Food and Drug Administration anticancer drug approval trends from 2016 to 2018 for lung, colorectal, breast, and prostate cancer.
    Ribeiro TB; Ribeiro A; Rodrigues LO; Harada G; Nobre MRC
    Int J Technol Assess Health Care; 2020; 36(1):20-28. PubMed ID: 31775939
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Role of tyrosine kinase inhibitors in lung cancer.
    Ansari J; Palmer DH; Rea DW; Hussain SA
    Anticancer Agents Med Chem; 2009 Jun; 9(5):569-75. PubMed ID: 19519298
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Novel compounds in the treatment of lung cancer: current and developing therapeutic agents.
    Bao R; Chan P
    J Exp Pharmacol; 2011; 3():21-34. PubMed ID: 27186107
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Polymorphisms to predict outcome to the tyrosine kinase inhibitors gefitinib, erlotinib, sorafenib and sunitinib.
    Erdem L; Giovannetti E; Leon LG; Honeywell R; Peters GJ
    Curr Top Med Chem; 2012; 12(15):1649-59. PubMed ID: 22978339
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Effects of removing reimbursement restrictions on targeted therapy accessibility for non-small cell lung cancer treatment in Taiwan: an interrupted time series study.
    Hsu JC; Wei CF; Yang SC
    BMJ Open; 2019 Mar; 9(3):e022293. PubMed ID: 30878976
    [TBL] [Abstract][Full Text] [Related]  

  • 15. A systematic review of the cost-effectiveness of targeted therapies for metastatic non-small cell lung cancer (NSCLC).
    Lange A; Prenzler A; Frank M; Golpon H; Welte T; von der Schulenburg JM
    BMC Pulm Med; 2014 Dec; 14():192. PubMed ID: 25471553
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Systemic treatment for advanced (stage IIIb/IV) non-small cell lung cancer: more treatment options; more things to consider. Introduction.
    Bunn PA; Thatcher N
    Oncologist; 2008; 13 Suppl 1():1-4. PubMed ID: 18263768
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Epidermal growth factor receptor-targeted agents for lung cancer.
    Martin P; Kelly CM; Carney D
    Cancer Control; 2006 Apr; 13(2):129-40. PubMed ID: 16735987
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Erlotinib or gefitinib for the treatment of relapsed platinum pretreated non-small cell lung cancer and ovarian cancer: a systematic review.
    Murphy M; Stordal B
    Drug Resist Updat; 2011 Jun; 14(3):177-90. PubMed ID: 21435938
    [TBL] [Abstract][Full Text] [Related]  

  • 19. [New biological treatments for lung cancer].
    Zalcman G; Richard N; Bergot E
    Rev Pneumol Clin; 2007 Feb; 63(1):20-8. PubMed ID: 17457280
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Targeted therapies in small cell lung cancer.
    Lu HY; Wang XJ; Mao WM
    Oncol Lett; 2013 Jan; 5(1):3-11. PubMed ID: 23255884
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 12.